Navigation Links
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
Date:9/30/2009

s of AT2220 on glycogen reduction in an appropriate transgenic mouse model of Pompe disease. Preliminary results of this study demonstrate consistent glycogen reduction across a range of different tissues, including heart, diaphragm and multiple skeletal muscles. Glycogen is the substrate that accumulates in the cells of patients with Pompe disease, which is believed to result in the clinical symptoms of the disease. The Company expects to present the results of this and other preclinical studies at appropriate scientific conferences in 2010.

Additionally, Amicus continues to be encouraged by the results of preclinical studies designed to evaluate the use of AT2220 in combination with enzyme replacement therapy (ERT). The Company expects to report additional data from these studies at scientific conferences in 2010.

About Pompe Disease

Pompe disease affects an estimated 5,000 to 10,000 individuals world-wide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive muscle weakness and respiratory insufficiency. A high majority of people with Pompe disease have the late onset form. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as ph
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... Global Quartz Tubing industry. For an overview analysis, ... classification, application, industry chain structure, industry overview, policy ... quartz tubing industry has witnessed rapid development ... number of acquisitions. This report mentions quartz tubing ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... December 15, 2014 METTLER TOLEDO ... PVM tool, ParticleView V19 with PVM technology ... probe-based particle vision and measurement tool continuously captures ... conditions. ParticleView V19 then automatically prepares a report ... particle size and concentration changes. This compelling blend ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... KVISTGAARD, Denmark, March 27 Today Bavarian,Nordic published the ... company,s website: http://www.bavarian-nordid.com . , ... DKK 209 million with a,loss before tax of DKK ... guidance. At year-end 2008, net free cash and cash ...
... March 27 Zinsser Analytic and ThalesNano today announced ... in the territory of Germany, Switzerland and Austria."We are ... Zinsser is a leader in automation and a brand ... Ferenc Darvas, president and chairman of ThalesNano Inc. ...
... March 26 On March 18th, Frost & ... research award. The award was given in recognition of ... , which uses glycated albumin to measure ... http://www.newscom.com/cgi-bin/prnh/20090326/LA89768 )Diabetes is one of the ...
Cached Biology Technology:Bavarian Nordic Publishes its Annual Results 2008 2Bavarian Nordic Publishes its Annual Results 2008 3Bavarian Nordic Publishes its Annual Results 2008 4Bavarian Nordic Publishes its Annual Results 2008 5Bavarian Nordic Publishes its Annual Results 2008 6Bavarian Nordic Publishes its Annual Results 2008 7Zinsser Analytic and ThalesNano Collaborate on Distributing Products 2Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech 2
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... DALLAS March 31, 2010 UT Southwestern Medical Center ... some people are more susceptible to stress than others. ... after experiencing a stressful event, animals that were more susceptible ... nerve cells in the brain. Specifically, the cells that these ...
... like a king, lunch like a prince and dinner like ... follow to prevent metabolic syndrome, according to a new University ... is characterized by abdominal obesity, high triglycerides, insulin resistance and ... 30 in the International Journal of Obesity, examined ...
... powerful pulse . . . A ... Laboratory,s Spallation Neutron Source shatters previous field strength limits ... with SNS researchers to develop the new technique, which ... sample to extremely high magnetic fields. ,Neutron scattering analysis ...
Cached Biology News:New brain nerve cells key to stress resilience, UT Southwestern researchers find 2New brain nerve cells key to stress resilience, UT Southwestern researchers find 3Bacon or bagels? Higher fat at breakfast may be healthier than you think, says UAB research 2Story tips from the US Department of Energy's Oak Ridge National Laboratory April 2010 2
Request Info...
Request Info...
... Concentration Basement Membrane Extract Cultrex HC20+ ... vivo applications where higher protein concentrations ... strength, and elevated levels of tumor ... of lot-to-lot consistency and controlled protein ...
Cultrex 3D Culture Matrix BME....
Biology Products: